NT Pharma proposes divestment of NT Overseas, which holds a 25.30% stake in Beijing Kangchen Biotech

Bulletin Express

May 29

China NT Pharma Group Company Limited (NT Pharma) has announced plans to dispose of part or all of its equity interest in NT Pharma (Overseas) Holding Co., Ltd. (NT Overseas) to ease liquidity pressure and support an ongoing strategic transformation.

NT Overseas, an indirect wholly owned subsidiary of NT Pharma, controls 100% of NT Pharma (Asia) Company Limited, which in turn owns 25.30% of Beijing Kangchen Biotech Co., Ltd. A successful transaction would therefore indirectly transfer NT Pharma’s minority stake in Beijing Kangchen Biotech.

The board confirmed that only preliminary, directional discussions with potential buyers have been held. No substantive terms, legally binding agreements or memoranda of understanding have been reached. Completion of any deal remains subject to due-diligence results, buyer offers, regulatory approvals and negotiation of definitive documents.

NT Pharma stated it will issue further announcements in line with Hong Kong Stock Exchange requirements once substantive progress—such as receipt of a formal offer, signing of a letter of intent or termination of discussions—occurs.

Shareholders and prospective investors are urged to exercise caution when trading NT Pharma shares and to seek professional advice if in doubt.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1131121049"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131121049\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131121049?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131121049","market":"us","top_or_hot":-1,"title":"NT Pharma proposes divestment of NT Overseas, which holds a 25.30% stake in Beijing Kangchen Biotech","media":"Bulletin Express","content":"<p>China NT Pharma Group Company Limited (NT Pharma) has announced plans to dispose of part or all of its equity interest in NT Pharma (Overseas) Holding Co., Ltd. (NT Overseas) to ease liquidity pressure and support an ongoing strategic transformation.</p>\n<p>NT Overseas, an indirect wholly owned subsidiary of NT Pharma, controls 100% of NT Pharma (Asia) Company Limited, which in turn owns 25.30% of Beijing Kangchen Biotech Co., Ltd. A successful transaction would therefore indirectly transfer NT Pharma’s minority stake in Beijing Kangchen Biotech.</p>\n<p>The board confirmed that only preliminary, directional discussions with potential buyers have been held. No substantive terms, legally binding agreements or memoranda of understanding have been reached. Completion of any deal remains subject to due-diligence results, buyer offers, regulatory approvals and negotiation of definitive documents.</p>\n<p>NT Pharma stated it will issue further announcements in line with Hong Kong Stock Exchange requirements once substantive progress—such as receipt of a formal offer, signing of a letter of intent or termination of discussions—occurs.</p>\n<p>Shareholders and prospective investors are urged to exercise caution when trading NT Pharma shares and to seek professional advice if in doubt.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NT Pharma proposes divestment of NT Overseas, which holds a 25.30% stake in Beijing Kangchen Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNT Pharma proposes divestment of NT Overseas, which holds a 25.30% stake in Beijing Kangchen Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-29 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China NT Pharma Group Company Limited (NT Pharma) has announced plans to dispose of part or all of its equity interest in NT Pharma (Overseas) Holding Co., Ltd. (NT Overseas) to ease liquidity pressure and support an ongoing strategic transformation.</p>\n<p>NT Overseas, an indirect wholly owned subsidiary of NT Pharma, controls 100% of NT Pharma (Asia) Company Limited, which in turn owns 25.30% of Beijing Kangchen Biotech Co., Ltd. A successful transaction would therefore indirectly transfer NT Pharma’s minority stake in Beijing Kangchen Biotech.</p>\n<p>The board confirmed that only preliminary, directional discussions with potential buyers have been held. No substantive terms, legally binding agreements or memoranda of understanding have been reached. Completion of any deal remains subject to due-diligence results, buyer offers, regulatory approvals and negotiation of definitive documents.</p>\n<p>NT Pharma stated it will issue further announcements in line with Hong Kong Stock Exchange requirements once substantive progress—such as receipt of a formal offer, signing of a letter of intent or termination of discussions—occurs.</p>\n<p>Shareholders and prospective investors are urged to exercise caution when trading NT Pharma shares and to seek professional advice if in doubt.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01011","symbol_name":"泰凌医药","start_time":0,"source_url":"","article_id":"1131121049","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131121049","pubTimestamp":1780045457,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China NT Pharma Group Company Limited (NT Pharma) has announced plans to dispose of part or all of its equity interest in NT Pharma (Overseas) Holding Co., Ltd. (NT Overseas) to ease liquidity...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01011":"泰凌医药"},"translate_title":"泰凌医药拟剥离持有北京康辰生物25.30%股权的泰凌海外","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"China NT Pharma Group Company Limited (NT Pharma) has announced plans to dispose of part or all of its equity interest in NT Pharma (Overseas) Holding Co., Ltd. (NT Overseas) to ease liquidity pressure and support an ongoing strategic transformation.\nNT Overseas, an indirect wholly owned subsidiary of NT Pharma, controls 100% of NT Pharma (Asia) Company Limited, which in turn owns 25.30% of Beijing Kangchen Biotech Co., Ltd. A successful transaction would therefore indirectly transfer NT Pharma’s minority stake in Beijing Kangchen Biotech.\nThe board confirmed that only preliminary, directional discussions with potential buyers have been held. No substantive terms, legally binding agreements or memoranda of understanding have been reached. Completion of any deal remains subject to due-diligence results, buyer offers, regulatory approvals and negotiation of definitive documents.\nNT Pharma stated it will issue further announcements in line with Hong Kong Stock Exchange requirements once substantive progress—such as receipt of a formal offer, signing of a letter of intent or termination of discussions—occurs.\nShareholders and prospective investors are urged to exercise caution when trading NT Pharma shares and to seek professional advice if in doubt.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}